Immuron (NASDAQ: IMRN; ASX: IMC), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron's technology platform utilizes highly specific vaccines for the generation of hyperimmune antibody-rich bovine colostrum, providing a means of antimicrobial therapy without the drawbacks of antibiotics to treat gut-mediated diseases.
A live Q&A session, open to current and prospective investors, will immediately follow CEO Gary Jacob presentation.
For more information on Immuron (NASDAQ: IMRN), visit http://www.imrninfo.com/
View investor deck